Opendata, web and dolomites

THERADNET SIGNED

International NETwork for training and innovations in THErapeutic RADiation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERADNET project word cloud

Explore the words cloud of the THERADNET project. It provides you a very rough idea of what is the project "THERADNET" about.

tumor    situation    outcome    primary    alone    patients    innovation    tissues    care    biologically    window    training    radiotherapy    expertise    immune    death    cancer    reactions    radiation    prior    plasticity    regrowth    limiting    altered    treatment    surrounding    clinical    hypotheses    outstanding    irradiated    co    50    substantial    improvements    community    dampen    multimodality    international    radiobiological    disease    approximately    close    benefit    critical    innovative    medicine    industry    45    academia    performed    mass    precision    translational    premises    acquired    understand    small    science    pursuit    recurrence    models    modalities    collaborations    successful    stimulate    employability    guarantee    biological    therapeutic    intrinsic    integration    cooperate    microenvironment    resistance    individual    metastatic    normal    optimized    widen    personalized    health    integrating    students    dose    standard    radiobiology    network    cured    combined    countries    combatting    metabolism    adverse    despite    innovations    60    sectors    outgrowth    therapy   

Project "THERADNET" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT ZURICH 

Organization address
address: RAMISTRASSE 71
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 4˙026˙324 €
 EC max contribution 4˙026˙324 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2023-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT ZURICH CH (ZURICH) coordinator 562˙553.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 606˙345.00
3    INSTITUT CURIE FR (PARIS) participant 549˙604.00
4    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 531˙239.00
5    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) participant 512˙640.00
6    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 505˙576.00
7    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 505˙576.00
8    WESTDEUTSCHES PROTONENTHERAPIEZENTRUM ESSEN (WPE) GGMBH DE (ESSEN) participant 252˙788.00

Map

 Project objective

Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERADNET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERADNET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

REPOL (2020)

CHARACTERIZATION, COMPATIBILIZATION, PROCESSING AND PROPERTIES OF RECYCLED POLYOLEFINS

Read More